EIC Transition Challenge: RNA-based therapies and diagnostics for complex or rare genetic diseases
Summary
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Programme Name
Programme Description
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Call
Detailed Call Description
EIC Transition funds innovation activities that go beyond the experimental proof of principle in laboratory. It supports both the maturation and validation of a novel technology from the lab to the relevant application environments (by making use of prototyping, formulation, models, user testing or other validation tests) as well as explorations and development of a sustainable business case and business model towards commercialisation.
Proposals submitted to this EIC Transition Challenge call should focus on one or more of the following specific objectives:
- advance, beyond the state-of-the-art, RNA delivery methods, including robust mRNA formulations, that would enable effective and safe delivery of mRNA into the cells;
- design, develop and preclinical validate of novel miRNAs (miRNA lncRNA, tRNA or siRNA-based) therapies for complex or rare genetic diseases;
- develop and validate novel RNA-based diagnostics and RNA-based predictive biomarkers that would allow for early and more accurate diagnosis and for favourable or non- post-treatment prognosis, respectively.
Financing percentage by EU or other bodies / Level of Subsidy or Loan
100%
Eligibility For Participation Notes
A single legal entity established in a Member State or an Associated Country (‘mono-beneficiary’) if you are an SME or a research performing organisation (university, research or technology organisation, including teams, individual Principle Investigators and inventors in such institutions who intend to form a spinout company). Larger companies (i.e. which do not qualify as SMEs) are not eligible to apply as a single legal entity; or
- A small consortium of two independent legal entities from two different Member States or Associated Countries, or
- A consortium of minimum three and maximum five independent legal entities (‘multi-beneficiary’) following standard rules i.e. must include at least one legal entity established in a Member State and at least two other independent legal entities, each established in different Member States or Associated Countries.
Consortia of more than 5 partners will be deemed ineligible.
Programme Category
EU Competitive ProgrammesTotal Budget
€131,360,126Thematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Educational Institutions
- Large Enterprises
- Local Authorities
- Private Bodies
- Researchers/Research Centers/Institutions
- Small and Medium Enterprises (SMEs)
Call Opening Date
01/03/2022Call Closing Date
04/05/2022National Contact Point(s)
Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia
P.O.Box 23422, 1683 Nicosia
Phone Number: +357 22205000
Email Address: support@research.org.cy
Website: https://www.research.org.cy/en/
Contact Persons:
Ms Katerina Karakasidou
Scientific Officer
Contact Phone: +357 22 205 036
Contact Email: kkarakasidou@research.org.cy
Dr Kalypso Sepou
Head of European Programmes Department
Contact Phone: +357 22 205066
Contact Email: kalypso@research.org.cy
(Publish Date: 01/03/2022-for internal use only)
EU Contact Point
Research Enquiry Service: https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en